{"type":"trials","record":{"id":510,"source_id":"clinicaltrials-gov","external_id":"NCT07637487","title":"Tocotrienol Supplementa as A Senolytic Agent in Middle-aged Adults","brief_summary":"The goal of this clinical trial is to determine whether tocotrienol works as a senolytic agent to delay age-related biological changes in middle-aged adults. The study will also evaluate the safety of tocotrienol supplementation. The main questions it aims to answer are: Does tocotrienol reduce markers of cellular senescence, inflammation, oxidative stress, and mitochondrial dysfunction? What health changes or medical issues occur in participants taking tocotrienol? Researchers will compare tocotrienol-rich fraction to a placebo (a look-alike capsule with no active ingredient) to determine whether tocotrienol is effective in modulating aging-related pathways. Participants will: Take tocotrienol (200 mg/day) or a placebo daily for 6 months Attend study visits at baseline, 3 months, and 6 months for clinical assessments and laboratory tests Undergo blood sampling and health evaluations, including measures of senescence-associated secretory phenotype (SASP), inflammation, oxidative stress, mitochondrial function, vascular health, skin status, cognitive function, body composition, and bone mineral density. Complete questionnaires related to diet throughout the study period This study aims to provide clinical evidence on the potential of tocotrienol as a senolytic intervention for promoting healthy aging and reducing the risk of age-related diseases.","overall_status":"Recruiting","phases":[],"study_type":"INTERVENTIONAL","sponsor":"National University of Malaysia","enrollment":220,"countries":["Malaysia"],"start_date":"2023-10-31","completion_date":"2027-01-30","last_update_date":"2026-06-09","source_url":"https://clinicaltrials.gov/study/NCT07637487","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-14T02:45:05.518263+00:00","last_seen_at":"2026-09-25T06:20:04.694+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"35 Years to 50 Years","comparator":"Placebo","organization":"National University of Malaysia","interventions":["Treatment","Placebo"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Blood pressure — Baseline, Month 3 and Month 6","Changes in Advanced Glycation End Products (AGEs) — Baseline, Month 3, and Month 6","Changes in Protein Carbonyl — Baseline, Month 3, and Month 6","Change in Malondialdehyde (MDA) — Baseline, Month 3, and Month 6","Change in DNA Damage — Baseline, Month 3, and Month 6","Body Composition assessment — Baseline, Month 3, and Month 6","Food intake questionnaire — Baseline, Month 3, and Month 6","Changes in SASP Gene expression — Baseline, Month 3, and Month 6","Change in SASP Protein expression — Baseline, Month 3, and Month 6","Change in Tumor Necrosis Factor-Alpha (TNF-α) — Baseline, Month 3, and Month 6","Change in Inteleukin-6 (IL-6) — Baseline, Month 3, and Month 6","Change in ATP production — Baseline, Month 3, and Month 6","Change in Mitochondrial Complex V Enzyme Activity — Baseline, Month 3, and Month 6","Change in Mitochondrial Membrane Potential — Baseline, Month 3, and Month 6","Change in Plasma Alpha-Tocotrienol Concentration — Baseline, Month 3, and Month 6","Change in Plasma Gamma- Tocotrienol Concentration — Baseline, Month 3, and Month 6","Change in Total Plasma Tocotrienol Concentration — Baseline, Month 3, and Month 6","Muscle mass — Baseline and Month 6","Fat mass — Baseline and Month 6","Bone mineral content (BMC) — Baseline and Month 6"],"design_description":"RANDOMIZED · PARALLEL · PREVENTION · TRIPLE","source_has_results":false},"controlled_terms":["Healthy","Treatment","Placebo"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: senolytic.","quality_checked_at":"2026-09-25T06:20:05.499352+00:00","duplicate_cluster_key":"id:nct07637487","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-10-31 to 2027-01-30","comparator":"Placebo","confidence":"structured-source","population":"ALL · 35 Years to 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:04.701Z","intervention":["Treatment","Placebo"],"participants":220,"study_design":"RANDOMIZED · PARALLEL · PREVENTION · TRIPLE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Blood pressure — Baseline, Month 3 and Month 6","Changes in Advanced Glycation End Products (AGEs) — Baseline, Month 3, and Month 6","Changes in Protein Carbonyl — Baseline, Month 3, and Month 6","Change in Malondialdehyde (MDA) — Baseline, Month 3, and Month 6","Change in DNA Damage — Baseline, Month 3, and Month 6","Body Composition assessment — Baseline, Month 3, and Month 6","Food intake questionnaire — Baseline, Month 3, and Month 6","Changes in SASP Gene expression — Baseline, Month 3, and Month 6","Change in SASP Protein expression — Baseline, Month 3, and Month 6","Change in Tumor Necrosis Factor-Alpha (TNF-α) — Baseline, Month 3, and Month 6","Change in Inteleukin-6 (IL-6) — Baseline, Month 3, and Month 6","Change in ATP production — Baseline, Month 3, and Month 6","Change in Mitochondrial Complex V Enzyme Activity — Baseline, Month 3, and Month 6","Change in Mitochondrial Membrane Potential — Baseline, Month 3, and Month 6","Change in Plasma Alpha-Tocotrienol Concentration — Baseline, Month 3, and Month 6","Change in Plasma Gamma- Tocotrienol Concentration — Baseline, Month 3, and Month 6","Change in Total Plasma Tocotrienol Concentration — Baseline, Month 3, and Month 6","Muscle mass — Baseline and Month 6","Fat mass — Baseline and Month 6","Bone mineral content (BMC) — Baseline and Month 6"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"senolytics","is_published":true,"match_reasons":["Title contains controlled term: senolytic.","Abstract contains controlled term: senolytic, cellular senescence.","Abstract supplies longevity context: aging, senescence.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Senolytics","slug":"senolytics"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/510","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}